Merck Posts Q2 EPS Beat Revenue Slips
(NYSE:MRK), a leading developer of prescription medicines, vaccines, and animal health products, released its second-quarter 2025 results on July 29, 2025. The most notable news was a beat on earnings per share, with non-GAAP EPS at $2.13 versus estimates of $2.02, a 5 % outperformance, even as GAAP revenue of $15.8 billion fell 0.58% short of consensus expectations. The quarter saw continued sales strength from its blockbuster oncology drug KEYTRUDA, which generated $8.0 billion in sales, but a steep drop in GARDASIL vaccine sales due to demand declines in China. Overall, the period highlighted both the resilience of Merck’s core oncology franchise and ongoing challenges in selected vaccine and international markets.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
(NYSE:MRK) is a global pharmaceutical company specializing in innovative prescription medicines, vaccines, and animal health products. Its top-selling therapy is KEYTRUDA, an immuno-oncology drug that targets advanced and early-stage cancers across many indications. The company’s broader portfolio also includes important vaccines like GARDASIL (human papillomavirus vaccine), diabetes drugs, hospital acute care medicines, and a robust animal health division.
Source Fool.com
Merck KGaA Aktie
Positive Einschätzungen für Merck KGaA überwiegen: Mehrere Buy-, keine Sell-Einschätzungen.
Für Merck KGaA sieht die Community ein Kursziel von 157 €, was eine erhebliche Steigerung um über 20% gegenüber dem aktuellen Kurs von 107.8 € bedeutet.
